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Cyclin-dependent kinases regulate the cell cycle
and transcription in higher eukaryotes. We have
determined the crystal structure of the transcription
kinase Cdk13 and its Cyclin K subunit at 2.0 A˚ reso-
lution. Cdk13 contains a C-terminal extension helix
composed of a polybasic cluster and a DCHEL motif
that interacts with the bound ATP. Cdk13/CycK
phosphorylates both Ser5 and Ser2 of the RNA poly-
merase II C-terminal domain (CTD) with a preference
for Ser7 pre-phosphorylations at a C-terminal posi-
tion. The peptidyl-prolyl isomerase Pin1 does not
change the phosphorylation specificities of Cdk9,
Cdk12, and Cdk13 but interacts with the phosphory-
lated CTD through its WW domain. Using recombi-
nant proteins, we find that flavopiridol inhibits Cdk7
more potently than it does Cdk13. Gene expression
changes after knockdown of Cdk13 or Cdk12 are
markedly different, with enrichment of growth
signaling pathways for Cdk13-dependent genes.
Together, our results provide insights into the struc-
ture, function, and activity of human Cdk13/CycK.
INTRODUCTION
Higher organisms have evolved a unique structure in the RNA
polymerase II (RNAPII) to coordinate transcription and the atten-
dant processing of pre-mRNA molecules. The largest subunit
Rpb1 of RNAPII contains a C-terminal extension, termed the
C-terminal domain, or CTD, which is composed of multiple re-
peats of the hepta-sequence Y1S2P3T4S5P6S7. The number of
repeats varies between 26 in yeast and 52 in humans and is
thought to correlate with the genomic complexity of the organ-
ism (Buratowski 2009; Corden 2013; Eick and Geyer, 2013). In
addition, alterations from the consensus sequence occur in
higher eukaryotes with a change in position 7 from serine to
lysine prevailing in the distal part of the human CTD. The repet-
itive structure of the CTD is thought to act as a binding scaffold320 Cell Reports 14, 320–331, January 12, 2016 ª2016 The Authorsfor transcription associated factors. The five hydroxyl group con-
taining residues Tyr1, Ser2, Thr4, Ser5, and Ser7 are all suscep-
tible to post-translational modifications (PTMs) combined with a
cis/trans isomerization of the two intermediate prolines, Pro3 and
Pro6. The reversible modifications by phosphorylation or
O-linked glycosylation as well as acetylation and methylation
of basic residues open a plethora of possible combinations of
PTMs, often described as RNAPII CTD code.
Phosphorylation of the three serine residues within the CTD is
tightly linked to the phases of RNAPII-mediated transcription
(Adelman and Lis, 2012). At first, the unphosphorylated polymer-
ase is recruited into the pre-initiation complex at open chromatin
structures. In a simplifiedmodel, phosphorylation of Ser7 (pSer7)
starts the transcription cycle until an additional pause step stalls
the polymerase about 50 nucleotides downstream of the tran-
scription start site (TSS). To overcome this promoter proximal
pausing, Ser5 is phosphorylated, potentially in conjunction with
Ser7, leading to the robust elongation of transcripts. On amolec-
ular level, Ser7 phosphorylation primes the CTD for further mod-
ifications (Czudnochowski et al., 2012; St Amour et al., 2012),
but, whereas Ser7 phosphorylation levels stay high during the
transcription process, the pSer5 signal decreases steadily to-
ward the poly-adenylation site by the action of phosphatases.
Ser2 phosphorylation instead increases toward the transcription
termination site (TTS), consistent with the recruitment of 30 RNA-
processing factors by pSer2 marks (Davidson et al., 2014). The
phosphorylation signals are removed by phosphatases during
the termination process, giving way for a new transcription cycle
of the polymerase.
Cyclin-dependent kinases (CDKs) play major roles in the regu-
lation of the cell cycle and transcription. Five mammalian CDKs
have been described to date as transcription regulating kinases
together with their corresponding cyclin subunits: Cdk7/Cyclin H
as components of the general transcription factor TFIIH
(Gr€unberg and Hahn, 2013), Cdk8/Cyclin C as components of
the Mediator kinase module (Allen and Taatjes, 2015), Cdk9/
Cyclin T1 or T2 that constitute the active form of the positive tran-
scription elongation factor (P-TEFb) (Peterlin and Price, 2006),
and Cdk12/Cyclin K and Cdk13/Cyclin K as the latest members
of RNAPII CTD kinases (Bartkowiak et al., 2010; Blazek et al.,
2011). A precise assignment of the various CDKs to the different
serine phosphorylations within the transcription cycle is not yet
clear, as some promiscuity in the specificity of the kinases per-
sists. However, Cdk9 is commonly described as a transcription
elongation kinase that is located at the TSS in line with its func-
tion to overcome the promoter proximal arrest (Ghamari et al.,
2013). Cdk7 in contrast initiates transcription, both by phosphor-
ylating Ser7 of the CTD and by its ability to phosphorylate the
activating threonine in the T-loop of CDKs (Larochelle et al.,
2012).
Human Cdk12 and Cdk13 are large proteins with molecular
weights of 164 and 165 kDa, respectively. The proteins share
43% sequence identity and harbor a central kinase domain. In
contrast to CDKs 7, 8, and 9, human kinases Cdk12 and
Cdk13 contain expanded regions of serine-arginine (SR) motifs
in their N-terminal regions. These regions span residues 130–
380 in Cdk12 and 200–435 in Cdk13, respectively, linking the ki-
nases to the SR protein family involved in RNA processing and
pre-mRNA splicing (Zhou and Fu, 2013; Ghosh and Adams,
2011). Accordingly, Cdk13 was demonstrated to interact with
the splicing factor SRSF1 and to regulate alternative splicing of
HIV (Berro et al., 2008). Cdk12 in turn was shown to regulate
DNA-damage response genes and somatic gene mutations of
the kinase were found in multiple cancers as high-grade serous
ovarian carcinoma (The Cancer Genome Atlas Research
Network, 2011; Ekumi et al., 2015; Joshi et al., 2014). However,
the exact roles of Cdk13 and Cdk12 in these processes are yet to
be explored.
In an effort to understand the molecular basis of Cdk13 func-
tion, we determined the crystal structure of the kinase/cyclin do-
mains of humanCdk13/CycK at 2.0 A˚ resolution. Cdk13 contains
a C-terminal extension helix following the canonical kinase
domain that interacts with the bound ATP substrate. Flavopiridol
is a poor inhibitor of Cdk13 activity but inhibits Cdk7 more
potently, explaining its potency in downregulating transcription
associated processes. The cis/trans peptidyl-prolyl isomerase
Pin1 does not change the phosphorylation specificity of
Cdk13/CycK for Ser5 and Ser2 sites, while pre-incubation of a
CTD substrate with Cdk9 showed a small increase in Cdk13 ac-
tivity. Finally, we find that Cdk13 and Cdk12 regulate different
sets of genes, with Cdk13 activity mostly involved in growth
signaling pathways.
RESULTS
Structure of the Cdk13/Cyclin K Complex
Human Cdk13 is an unusually large kinase that harbors a central
kinase domain flanked by an N-terminal SR region and a C-ter-
minal region of low complexity (Figure 1A). Its corresponding
cyclin partner CycK contains a cyclin-box domain followed by
a wide-stretched proline-rich region with 42% proline content
over 220 amino acids. For structure determination, the kinase
and cyclin box domains of human Cdk13/CycK were expressed
in baculovirus infected insect cells co-transfected with the CDK
activating kinase CAK1 from S. cerevisiae. The complex was pu-
rified to homogeneity by affinity chromatography and gel filtra-
tion analysis (Figure S1). Crystals were grown in the presence
of ADP, aluminum fluoride, and the substrate peptide P-pS-
YSPTSP-pS-YSPT by the hanging drop diffusion techniqueC(see Experimental Procedures). The crystallographic phases
were solved by molecular replacement with the coordinates of
Cdk12/CycK as a search model and the structure was deter-
mined to a resolution of 2.0 A˚. The protein complex was refined
to an Rwork of 19.5% and Rfree of 24.7% with excellent stereo-
chemistry (Table S1). Two Cdk13/CycK heterodimers form the
asymmetrical unit cell of the protein crystal. No crystallographic
density was observed for the substrate peptide but only for the
AlF3 transition state mimic and two magnesium ions (Figure 1B).
Cdk13 exhibits the typical kinase fold consisting of an N-termi-
nal lobe (aa 695–794) and a C-terminal lobe (aa 795–998) that
share 46.9% sequence identity to Cdk9 and 41.4% sequence
identity to Cdk2, respectively. The orientation of the aC helix,
also known as the 746PITAIRE helix (Figures 1B and 2), is in the
kinase active conformation, mediating contacts to the cyclin
subunit. The 855DFG motif at the start of the activation segment
and the activation segment itself adopt conformations that allow
access of the substrate to the catalytic site. Following the DFG
motif is a leucine, L858, indicative for the preference of a SPmotif
rather than a TP motif for phosphorylation (Chen et al., 2014a).
Similar to Cdk12, Cdk13 contains a C-terminal extension
segment (aa 999–1032) following the canonical cyclin box
domain that associates to the kinase domain (Figure 1C). A his-
tidine and a glutamate residue within this stretch, H1018 and
E1019, form water-mediated interactions to the ribose of the
bound nucleotide (Figure 1D). The interactions of this central
HE motif to the kinase domain are complemented by flanking
residues D1016 and L1020 that weakly interact with the N- and
C-terminal lobes of the kinase domain. The 1016DCHEL
sequence is succeeded by the polybasic region 1023KKRRRQK,
which is resolved in the second chain of Cdk13 up to M1031,
thought without displaying electron density for the side chains
of the positively charged amino acids (Figure S2). Its conforma-
tion reveals that the HE motif and the polybasic cluster form a
continuous helix adjacent to the kinase active center.
Cdk/Cyclin Complexes of Transcription Elongation
Kinases Adopt an Open Conformation
The orientation of the cyclin subunit with respect to the kinase
domain is rotated in Cdk13/CycK by 21 toward an open confor-
mation compared to the structure of Cdk2/CycA (Figure 3A). This
leads to exposure of the kinase active center as the first cyclin-
box domain of CycK is bent apart from the kinase T-loop
element. A similar arrangement has been observed for the
Cdk9/CycT1 complex and the Cdk12/CycK complex with rota-
tions of 26 and 24, respectively, compared to Cdk2/CycA (Fig-
ure 3B). One explanation for the twist of the two subunits with
respect to each other is that the phospho-threonine in the
T-loop segment of the kinase is coordinated only by two of the
three canonical arginine residues (Figure 2). Phospho-T871
within the activation segment is clearly visible in the electron
density map and forms salt bridges with R836 and R860 (Fig-
ure 3C). The third canonical arginine residue instead, R751 of
the PITAIRE motif, is about 8.1 A˚ apart from the phosphate
group. It forms an intermolecular salt bridge with the second
glutamate of the 105KVEE motif in CycK, which is conserved in
cyclins C, H, K, and T (Figure S3). These four cyclins are the
corresponding subunits to transcription regulating kinasesell Reports 14, 320–331, January 12, 2016 ª2016 The Authors 321
Figure 1. Structure of the Human Cdk13/CycK Complex
(A) Domain architectures of human Cdk13 (UniProt: Q14004) and human Cyclin K (O75909). Cdk13 contains an extended N-terminal serine-arginine (SR)-rich
region that spans 250 amino acids, followed by the central kinase domain. Human CycK consists of an N-terminal cyclin box domain followed by a region of low
complexity of more than 300 amino acids, containing more than 35% prolines.
(B) Overall structure assembly of Cdk13 (green) and CycK (beige). The ADP,AlF3 nucleotide and the phospho-threonine residue in the T loop segment of the
kinase are highlighted.
(C) Coordination of the C-terminal extension in Cdk13 following the canonical kinase domain. Residues 1001–1024 are shown as cartoon with the final 2Fo–Fc
electron density displayed at 1s. The structure of the Cdk13 kinase domain is shown as surface representation.
(D) Close up of the interactions of the C-terminal extension helix with the kinase domain and the bound nucleotide. H1018 and E1019 of the DCHELmotif in Cdk13
form water-mediated contacts to ADP complemented by interactions of D1016 with residues of the N- and C-terminal kinase lobes.Cdk8, 7, 12 and 13, and 9. A similar arrangement to Cdk13/CycK
is found in Cdk12/CycK, where the arginine residue of the
PITAIRE motif solely forms intermolecular interactions with the
cyclin subunit (Bo¨sken et al., 2014). The arginine of the PITALRE
sequence in Cdk9/CycT1 instead contacts both the phospho-
threonine of the T-loop and the second glutamate of the KVEE
motif (Schulze-Gahmen et al., 2013). For comparison, the three
canonical arginines R50, R126, and R150 of Cdk2 all form tight
salt bridges with the phospho-threonine pT160 (Russo et al.,
1996), with R50 of the PSTAIRE helix interacting additionally
with the first glutamate of the KFEE motif in Cyclin A (Figure 3D).
The orientation of the two subunits relative to each other is
reflected by the size of the buried surface area of the Cdk/cyclin
complexes. Whereas the buried surface area of Cdk2/CycA
involves both kinase lobes and cyclin boxes and encompasses
3,286 A˚2 (PDB:1JST) when counting both subunits, the Cdk13/
CycK interface of 2,002 A˚2 involves only the N-terminal lobe of
the kinase and the first cyclin box repeat. Likewise, Cdk12/
CycK covers a buried surface area of 2,161 A˚2 (PDB: 4NST)
and those of Cdk9/CycT1 1,819 A˚2 only (PDB: 3BLQ). The322 Cell Reports 14, 320–331, January 12, 2016 ª2016 The Authorssmaller interfaces thus correlate with the open conformation
of the Cdk/cyclin subunits, which appears as a common feature
of transcription elongation kinases. A detailed view on the
molecular interface between Cdk13 and CycK is shown in
Figure S4.
Cdk13 Is a Promiscuous Kinase for RNAPII CTD
Phosphorylations
We tested the activity of the Cdk13/CycK complex both for its
substrate recognition preference as well as for the phosphoryla-
tion specificity of the substrate. A series of synthetic CTD pep-
tides was analyzed, each containing three hepta repeats
followed by a polyethylene linker and two arginines. Besides
the consensus sequence, peptides uniformly phosphorylated
at positions Tyr1, Ser2, Thr4, Ser5, and Ser7 were used as well
as a Lys7 variant (Itzen et al., 2014). Cdk13/CycK showed the
highest activity on the pre-phosphorylated pSer7-CTD sub-
strate, whereas the non-phosphorylated consensus CTD pep-
tide was poorly recognized (Figure 4A). pThr4-, pSer2-, and
pTyr1-CTD peptides were all phosphorylated to a rather low
Figure 2. Sequence Alignment of Transcriptional CDKs
Sequence alignment of the kinase domains of humanCdk proteins involved in the regulation of transcription by RNA polymerase II. Secondary structure elements
are indicated for Cdk13 as determined here. The HE motif and the polybasic cluster in the C-terminal extension helix aK present in the transcription elongation
regulating kinases Cdk9 (UniProt: P50750), Cdk12 (UniProt: Q9NYV4), and Cdk13 are highlighted. The presence of these motifs correlates with a glycine residue
in helix aD (G800) that provides space of the assembly of the extension helix with the bound nucleotide. Accession numbers for Cdk8 and Cdk7 are as follows:
(UniProt: P49336 and P50613). Residues conserved in all CDKs are boxed red, and those that are similar are colored red. The sequence alignment was prepared
with MultAlin; the secondary structure alignment was prepared with ESPript.extent. The pSer5-CTD template and the K7-CTD peptide
instead were not recognized for phosphorylations.
In a following experiment, single Ser2, Ser5, or Ser7 phosphor-
ylation marks were placed in the N- or C-terminal repeat of the
CTD peptide, giving insights into the direction and recognition
specificity of the kinase. Only the peptide pre-phosphorylated
at the C-terminal Ser7 position (pS7-C) was decently phosphor-
ylated by Cdk13/CycK, albeit to less than 50% of the uniformly
pSer7-CTD substrate control (Figure 4B). The five other single
pre-phosphorylated peptides were phosphorylated to the
same extent as the consensus CTD. These data suggest that
the phosphorylation mark set by Cdk13/CycK is preferentially
attached N-terminal to an existing pSer7 site.
To determine the site of phosphorylation set by Cdk13/CycK,
we performed western blot analysis using monoclonal anti-
bodies generated against pSer2, pSer5, and pSer7 marks. InCaddition, the activity of native full-length proteins was compared
with recombinant CDK proteins as domains outside the can-
onical kinase fold could contribute to the phosphorylation
specificity. Flag-tagged full-length Cdk13 and Cdk12 with their
corresponding CycK subunit and Cdk9 proteins were expressed
in HCT116 cells as well as the kinase dead (KD) variants Cdk13
(D855N), Cdk12 (D877N), and Cdk9 (D167N), respectively. Incu-
bation of GST-CTD with anti-flag immuno-precipitated Cdk13
revealed equally strong signals for Ser2 and Ser5 phosphoryla-
tion, whereas no Ser7 phosphorylation was detected (Figure 4C).
A similar result was obtained for recombinant Cdk13/CycK
showing the same phosphorylation specificity as the native pro-
teins. Likewise, native and recombinant Cdk12/CycK complexes
exhibited a similar specificity for Ser2 and Ser5 phosphoryla-
tions, but again no Ser7 marks were set. In contrast, flag-tagged
immuno-precipitated full-length Cdk9 strongly phosphorylatedell Reports 14, 320–331, January 12, 2016 ª2016 The Authors 323
Figure 3. Transcription-Regulating Cdk/
Cyclin Complexes Adopt an Open Confor-
mation
(A) Superimposition of the two kinase subunits of
the Cdk13/CycK complex (colored green/wheat,
5EFQ) and the Cdk2/CycA complex (gray/red,
1JST) reveals that the cyclin subunit of the Cdk13/
CycK complex is twisted out toward an open
conformation of the kinase active site. The orienta-
tion of helix H1 of the two cyclins is displayed by an
arrow and the angle between the two helices given.
(B) Detailed view on the orientation of the first
canonical helix H1 in CycT1 (left) and CycK (right)
basedonasuperimpositionof thekinasesubunits in
the Cdk/cyclin complexes Cdk9/CycT1 with Cdk2/
CycA (3BLQ, 1JST) and Cdk12/CycK with Cdk2/
CycA (4NST, 1JST). The cyclin subunits are twisted
out by 26 and 24 relative to the kinase domains,
suggesting that this assembly is a common feature
of transcription elongation kinases.
(C) Close up of the phospho-threonine pT871 co-
ordination in the Cdk13 T-loop segment. The final
2Fo–Fc electron density is displayed at 1s (left).
Ionic interactions are formed between the two ca-
nonical CDK arginines R836 and R860 and the
phosphate group, whereas R751 of the PITAIRE
sequence in helix C mediates electrostatic con-
tacts with E108 of the 105KVEE motif in CycK but is
not directly contacting pT871.
(D) Salt bridge formation between the canonical
arginines R50, R126, and R150, and the phos-
phate group of pT160 is a hallmark of CDK acti-
vation. This conformation arranges the cyclin
subunit in a tight domain assembly.Ser5 of the CTD and a little Ser7, but no Ser2 sites, similarly as
observed before (Czudnochowski et al., 2012). The empty vector
control and the kinase dead variants instead showed no phos-
phorylations of the CTD on Ser2 and Ser7 and severely reduced
Ser5 phosphorylation intensity. Input controls by western blot
analyses using anti-flag and anti-CycK antibodies confirm the
integrity of the Cdk/cyclin complexes and display the amounts
of kinases used in the in vitro kinase assays (Figure 4D). The
contribution of the C-terminal extension helix to the kinase activ-
ity and specificity was probed by mutagenesis of the HE motif
and the polybasic cluster (Figure S5). Both motifs were mutated
to alanines, yet while the stability of the kinase was impaired for
the HE mutant, the preferences for Ser5 phosphorylations of the
full-length CTD remained unchanged.
Flavopiridol Inhibits Cdk7 More Potently Than It Does
Cdk13
The small molecular compound flavopiridol is a widely used ATP
competitive inhibitor of transcription elongation kinases (Baumli
et al., 2008; Wang and Fischer, 2008). We tested its ability to
inhibit Cdk13/CycK using recombinant proteins and the sub-
strate pS7-CTD. To a concentration of 0.2 mM Cdk13/CycK
and 1 mM ATP, flavopiridol was added in a concentration range
from 3.1 nM to 310 mM. From a plot of the kinase activity versus
the concentration of flavopiridol an in vitro IC50 value of 16.1 mM
was determined, rendering flavopiridol a rather poor inhibitor of
Cdk13 (Figure 5A). Intriguingly, structural analysis using the crys-324 Cell Reports 14, 320–331, January 12, 2016 ª2016 The Authorstal structure of Cdk9 bound to flavopiridol (Baumli et al., 2008)
superimposed with the structure of Cdk13 revealed a steric hin-
drance of flavopiridol with H1018 of the Cdk13 C-terminal exten-
sion helix (Figure 5B). The simultaneous occupancy of this site by
flavopiridol and the HE motif of the extension helix is therefore
precluded.
To further analyze the effect of flavopiridol in the inhibition of
transcription processes, we tested its efficacy in the inhibition
of Cdk7 kinase activity using recombinant protein. To a concen-
tration of 0.2 mM Cdk7/CycH/MAT1, flavopiridol was added in
increasing amounts from 1 nM to 100 mM concentration, using
1 mM ATP and 100 mM GST-CTD[9]KKK substrates. From a
sigmoidal fit, an IC50 value of 2.3 mM was determined for the in-
hibition of Cdk7 by flavopiridol (Figure 5C). Flavopiridol thus in-
hibits Cdk7 more potently than it does Cdk13. This effect is
remarkable given that Cdk7 is supposed to be the CDK acti-
vating kinase in mammals by its ability to phosphorylate the ki-
nases T-loops (Larochelle et al., 2012).
The high efficacy of flavopiridol as transcription elongation in-
hibiting compound was further analyzed in cells. Using targeted
small interfering RNAs (siRNAs), the expression levels of endog-
enous Cdk12 and Cdk13, respectively, were markedly reduced
in HCT116 cells (Figure 5D). Yet, compared to the use of a ran-
domized control siRNA, the changes in serine phosphorylation
are very small. The use of flavopiridol, however, strongly dimin-
ished the phosphorylation levels of all three serines, indicating
its broad inhibition of transcription processes.
Figure 4. Substrate Preferences of Cdk13/CycK Phosphorylation
(A) Activity of Cdk13/CycK for a panel of CTD substrate peptides. Three hepta repeats with either no or continuous phosphorylation marks were provided. Cdk13
showed the highest activity for a peptide containing Ser7 pre-phosphorylations. Minor activities were detected for Thr4 and Ser2 pre-phosphorylated peptides
and the consensus CTD, while no activity was seen on pSer5 and K7 peptides. A cartoon of the peptides used is shown on the right.
(B) Preferences of Cdk13 phosphorylations. Serine 2, 5, and 7 phosphorylations were set either in the N- or C-terminal repeat of a triple hepta-repeat substrate.
Overall, the activity of Cdk13 toward these peptides is weak and only slightly above the consensus CTD. The substrate with the C-terminal pS7 mark gained the
highest recognition preference. Data in (A) and (B) are reported as the mean ± SD of three independent experiments.
(C) In vitro kinase assays of Cdk13, Cdk12, and Cdk9 using GST-tagged full-length human CTD as substrate. Flag-tagged full-length kinases were immune-
precipitated from HCT116 cells and compared to recombinant Cdk13 (673–1039)/CycK (1–267) or Cdk12 (696–1082)/CycK (1–267). After incubation, GST-CTD
was subjected to western blot analysis using monoclonal antibodies (mAbs) specific for pSer2 (3E10), pSer5 (3E8), and pSer7 (4E12). EV, empty vector control;
KD, kinase dead mutants. Exposure times are indicated on the left.
(D) Display of the protein input used in the in vitro kinase assays. Equal amounts of full-length proteins were used as shown by western blots with anti-flag (upper
panel) and anti-CycK (middle panel) antibodies. Cdk13 purifications are free of Cdk9 contaminants as shown by western blot analysis with anti-Cdk9 antibody
(lower panel).Pin1 Does Not Change the Phosphorylation Preferences
of Transcription Kinases
The CTD contains two serine-proline motifs within each
consensus hepta repeat at positions 2/3 and 5/6, respectively.
A characteristic feature of the prolyl-peptide bond is a slow
rate of cis/trans isomerization (Schiene-Fischer et al., 2013).
The 18-kDa Pin1 protein is a human peptidyl-prolyl cis/trans
isomerase (PPIase) that binds to and isomerizes phosphorylated
S/T-P (pSer/pThr-Pro) motifs (Hanes, 2014). It contains an N-ter-
minal WW domain binding to pS and pT sites followed by the
PPIase domain (Figure 6A). To analyze whether the presence
of Pin1 affects the CTD phosphorylation mediated by transcrip-Ction kinases Cdk13, Cdk12, or Cdk9, we performed in vitro
kinase assays using 300 ng GST-CTD, 100 ng Pin1, and
immuno-precipitated full-length kinases Cdk13-flag/CycK,
Cdk12-flag/CycK, or Cdk9-flag/CycT1. For comparison,
100 ng of recombinant protein kinases Cdk13/CycK or Cdk12/
CycK was used.
Using antibodies against either pSer2 or pSer5 marks, we find
that the presence of Pin1 does not change the preferences of the
full-length kinases for phosphorylating Ser5 (Figure 6B). The
phosphorylation efficacy of the recombinant proteins Cdk13
and Cdk12, however, was markedly reduced upon addition of
Pin1. This effect can be attributed to the presence of the WWell Reports 14, 320–331, January 12, 2016 ª2016 The Authors 325
Figure 5. Flavopiridol Inhibits Cdk7 More
Potently than Cdk13
(A) Concentration series of flavopiridol for the inhi-
bition of Cdk13/CycK at 0.2 mM kinase concen-
tration. The IC50 value was determined to 16.1 ±
2.0 mM against Cdk13 using pS7-CTD as a sub-
strate.
(B) Model of the proposed position of flavopiridol in
the ATP pocket of Cdk13. Flavopiridol clashes with
the imidazole ring of H1018 in the C-terminal
extension helix of Cdk13. The model is based on a
superimposition of the Cdk9–flavopiridol structure
(3BLR) with the structure of Cdk13 determined
here.
(C) Concentration series of flavopiridol for the in-
hibition of Cdk7/CycH/MAT1 at 0.2 mM kinase
concentration. The IC50 value was determined to
2.3 ± 0.4 mM against Cdk7, using a CTD template
with nine hepta repeats. Data in (A) and (C) are re-
ported as the mean ± SD from three independent
experiments.
(D) Administration of flavopiridol leads to a
decrease in RNA pol II serine phosphorylations.
Flavopiridol was applied at 500 nM concentration
to HCT116 cells. Depletion of Cdk12 and Cdk13 by
siRNA, respectively, led to an approximate 2-fold
decrease of Ser2 and Ser5 phosphorylations but
did not affect Ser7 phosphorylation. Flavopiridol
instead diminished all serine phosphorylations of
the RNA pol II CTD, indicating its broad potency in
the regulation of transcription kinases.domain in Pin1 as deletion of the WW domain in the Pin1DWW
protein variant restores the full kinase activity (Figure 6C). At
the high molecular concentrations used in this experiment, the
WW domain of Pin1 could mask the CTD for its recognition by
the kinases. In a following experiment series, we tested whether
pre-incubation of the CTD with Cdk9/CycT1 could change the
ability of Cdk13 or Cdk12 to phosphorylate the CTD. Such effect
could be a priming of the substrate for further modifications to
determine, e.g., the succession of phosphorylation events in
the transcription cycle. GST-CTD was pre-incubated for
20 min with immuno-precipitated Cdk9/CycT1 or a kinase
dead variant of Cdk9. Pin1 was added optionally for 15 min
before recombinant kinases Cdk13/CycK or Cdk12/CycK were
subjected for another 40 min to the reaction. Again, a robust
Ser5 phosphorylation was seen for Cdk9 in the pre-incubation
time together with some Ser7 phosphorylation (Figure 6D, lanes
1 and 2). Addition of Cdk13/CycK or Cdk12/CycK led to addi-
tional Ser2 phosphorylation signals (lanes 3–6). Yet, compared
to the Cdk9 kinase dead control assay (lanes 7–12), the intensity
of the Ser2 phosphorylation bands were only 2- to 3-fold stron-
ger. We therefore conclude that a small increase in Ser2 phos-
phorylation by transcription kinases Cdk12 and Cdk13 can be
observed upon a priming step of the CTD with Cdk9. Addition
of Pin1, however, not much influenced the kinase phosphoryla-
tion specificities observed in these experiments.
Gene Expression Changes after Knockdown of Cdk13 or
Cdk12 Are Markedly Different
Given that the structures of the kinase domains of Cdk13 and
Cdk12 are rather similar and that both kinases phosphorylate326 Cell Reports 14, 320–331, January 12, 2016 ª2016 The Authorsthe CTD of RNAPII alike, we analyzed whether they also regulate
the expression of a similar set of genes. To address this question,
RNA expression profiling of HCT116 cells depleted of Cdk13 or
Cdk12 was performed (Figure 7). Cells were transfected with
control, Cdk13, or Cdk12 siRNAs in triplicate, and RNA was iso-
lated after 72 hr for expression analyses. Knockdown efficacy
was assessed by western blotting, confirming that Cdk13 and
Cdk12 were comparably depleted (Figure 7A). siRNA-mediated
knockdown of both kinases resulted in change of expression
of hundreds of genes (>1.4-fold with p < 0.05) (Figure 7B).
Namely, depletion of Cdk13 diminished expression of 250 genes
and increased expression of 242 genes, while knockdown of
Cdk12 downregulated 726 and upregulated 435 genes. For a
list of all the down- and upregulated genes, see Table S2.
To probe the gene expression changes after Cdk12 knock-
down, we selected three downregulated and two upregulated
genes from the expression microarray data for further analysis.
Cdk12 or Cdk13 were depleted by siRNA in HCT116 cells as
shown by western blot analysis (Figure S6A). The qRT-PCR
experiment confirmed the same expression pattern for Cdk12
depletion as observed in the microarray experiment, whereas
no significant change was seen upon Cdk13 depletion (Fig-
ure S6B). Likewise, efficient depletion of Cdk13 from cells (Fig-
ure S7A) led to decrease of mRNA levels in three out of four
selected genes found downregulated in the microarray (Fig-
ure S7B, upper panel), while two out of the three selected genes
found upregulated in the microarray assay were modestly upre-
gulated in qRT-PCR (Figure S7B, lower panel). To validate the
dependence of the randomly selected transcripts on Cdk13 ac-
tivity a rescue experiment was performed. Cells were depleted of
Figure 6. Pin1 Does Not Change the Phos-
phorylation Preferences of Cdk13/CycK
(A) The human peptidyl-prolyl isomerase Pin1
consists of an N-terminal WW domain followed by
the isomerase domain. Full-length Pin1 (1–163) and
a variant missing the N-terminal WW domain
(Pin1DWW, 50–163) was generated.
(B) Phosphorylation preferences of transcription
kinases Cdk13, Cdk12, and Cdk9, comparing flag-
tagged immunoprecipitated full-length Cdk/cyclin
proteins with recombinant protein complexes. Pin1
was optionally added in all kinase reactions. The
protein input using an anti-CycK antibody or an
anti-flag antibody is shown in the lower panels.
(C) The decrease of phosphorylation efficacy of
recombinant Cdk13/CycK and Cdk12/CycK de-
pends on theWWdomain in Pin1.Whereas full Pin1
reduced the phosphorylation profiles of the re-
combinant kinases, deletion of the WW domain
abrogated this ability. Such effect was not seen for
flag-tagged Cdk9.
(D) Pre-incubation of the CTD with Cdk9/CycT1
leads to slightly increased Ser2 phosphorylations.
A 20-min pre-incubation period of the CTD with
Cdk9/CycT1 shows the expected Ser5/Ser7
phosphorylations (lanes 1 and 2). Administration of
Cdk13/CycK or Cdk12/CycK leads to additional
pSer2 marks (lanes 3–6). The same treatment using
a kinase dead Cdk9 mutant shows significantly
lower Ser2 phosphorylation levels (lanes 7–12).
Addition of Pin1 only slightly reduced the phos-
phorylation signals of Cdk13 and Cdk12.Cdk13 by a single siRNA and after 30 hr expression of Cdk13
was either rescued or not by transfection of a Cdk13 siRNA-
insensitive plasmid. The efficacy of Cdk13 knockdown and
rescue is showed by western blotting (Figure S7C). qRT-PCR re-
sults confirmeddownregulation of all selectmRNAs (Figure S7D),
and rescue of Cdk13 expression resulted in increased expres-
sion of three out of four mRNAs.
To determine whether similar sets of genes and biological pro-
cesses were affected upon the knockdown of Cdk13 andCdk12,
we analyzed the overlap between down- or upregulated genes
for both kinases and performed gene ontology (GO) enrichment
analyses of affected genes using the DAVID software. Depletion
of Cdk13 and Cdk12 led to downregulation of largely different
sets of genes with common downregulation of only 62 genes
(Figure 7C, see Venn diagram on the left). Consistent with pub-
lished work (Blazek et al., 2011; Bartkowiak and Greenleaf,
2015; Liang et al., 2015), GO analysis of genes downregulated
upon Cdk12 knockdown indicated those genes to be enriched
in processes related to DNA replication and repair (Figure 7C,
upper bar graphs). In contrast, the GO analysis of Cdk13-depen-
dent genes showed enrichment of functions connected to
various extracellular and growth signaling pathways (Figure 7C,
middle bar graphs). Genes with lowered expression upon both,
Cdk12 and Cdk13, knockdowns are directing basic biological
processes such as regulation of phosphatase activity and glyc-
erolipid metabolism (Figure 7C, lower bar graphs). The analyses
of upregulated genes are consistent with the finding that mostly
different sets of genes and biological processes are regulated by
both kinases (Figure 7D). Only 49 genes were commonly upregu-Clated when either Cdk12 or Cdk13 was depleted; otherwise,
different genes increased their expression (Figure 7D). Concom-
itantly, the upregulated genes for both kinases were enriched in
different biological processes with the exception of their role
in neuron development (Figure 7D, see bar graphs on the right)
in line with findings of a recent study (Chen et al., 2014b).
Together, the expression array and bioinformatics analyses
show that Cdk12 and Cdk13 regulate expression of a markedly
different set of genes that regulate dissimilar biological pro-
cesses in human cells.
DISCUSSION
Cdk13 contains a C-terminal extension helix following the kinase
domain that interacts with the ribose of the bound ATP through
water-mediated contacts. A similar mode of interaction has
been found for Cdk12 and Cdk9 (Bo¨sken et al., 2014; Baumli
et al., 2012), suggesting this conformation a molecular feature
of transcription elongation regulating kinases. A polybasic clus-
ter of six positively charged residues (KKRRRQK) and an aro-
matic residue followed by a glutamic acid (HE) constitute the
conserved motifs of the extension helix in Cdk13. The associa-
tion of the basic patch in close proximity to the ATP binding
site could facilitate an electrostatic association to the highly
negatively charged RNAPII CTD and potentially also define a
register for the association of the phosphate groups within the
structure of the CTD (Figure S2). The extension segment also
creates a unique means for the specific interaction with potential
inhibitors. Superimposition of the structure of Cdk13,ADP withell Reports 14, 320–331, January 12, 2016 ª2016 The Authors 327
Figure 7. Knockdown of Cdk12 or Cdk13 Exhibits Different Gene Expression Profiles
(A) Knockdown efficacy of Cdk12 and Cdk13. Anti-Cdk12 and -Cdk13 antibodies show the expression levels of these kinases together with an actin antibody as
loading control.
(B) Genes that were differentially regulated after siRNA knockdown of Cdk12 (siCdk12) or Cdk13 (siCdk13) in HCT116 cells were determined by expression
microarray. Relative average expression levels of genes (x axis, log2) are plotted against their fold change (knockdown/control, y axis, log2). Significantly
downregulated genes (>1.4-fold, p < 0.05) or upregulated genes (>1.4-fold, p < 0.05) are indicated for Cdk12 knockdown in the left graph (downregulated, green;
upregulated, red) and for Cdk13 knockdown in the right graph (downregulated, blue; upregulated, yellow).
(C) The overlap in altered genes betweenCdk12 andCdk13 knockdownwas examined (Venn diagram, left panel). Biological processes in which altered genes are
involved were determined by GO enrichment analysis (DAVID, EASE threshold 0.05). The tenmost significantly represented biological processes are summarized
in bar graphs for Cdk12 knockdown (upper panel, green), for Cdk13 knockdown (middle panel, blue), or for genes that were similarly downregulated (lower panel,
purple). The x axis indicates the –log10 p value.
(D) The same analysis was performed for genes that were significantly upregulated (>1.4-fold, p < 0.05) after siRNA-mediated knockdown of Cdk12 (red) or Cdk13
(yellow). The overlap of altered genes for each knockdown was determined (Venn diagram, left). The top most significantly represented biological processes are
show for Cdk12 knockdown (red bars), for Cdk13 knockdown (yellow bars), or genes that were similarly upregulated after Cdk12 and Cdk13 knockdown
(orange bar).
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Cdk9,flavopiridol shows a steric clash of H1018 of the Cdk13 HE
motif with a benzol ring of flavopiridol (Figure 5). A compound de-
signed to mediate direct hydrogen bond interactions with the HE
residues of Cdk13 might instead exhibit a higher binding affinity
to this kinase and a higher specificity of inhibition. Of note, the
crystal structure of Cdk9 in complex with flavopiridol (Baumli
et al., 2008) (PDB: 3BLR) was determined with a C-terminally
truncated protein variant, missing the FE motif in Cdk9 and the
polybasic cluster.
The coordination of the phosphorylated threonine in the kinase
T-loop emerges as another specific feature of transcription regu-
lating CDKs. The formation of three salt bridges between argi-
nine residues from sequentially distant loop sections of the
kinase to the phosphorylated threonine of the T-loop is a hall-
mark of CDK activation (Johnson and Lewis, 2001). These salt
bridges lead to stabilization of the loop sections, mostly the
T-loop, a twist of the DFGxxR motif, the positioning of the cata-
lytic aspartate from the HRD motif, and a re-orientation of the
C-helix that contains the PITAIRE motif (Figures 1 and 2). Intrigu-
ingly, the third canonical salt bridge between the R from the
PITAIRE motif and the pT is not formed in either Cdk13 or
Cdk12 (Figure 3). Instead, a salt bridge is formed between the
arginine and the second glutamic acid of the KVEE motif, giving
room for the association of substrate residues.
The regulation of Cdk13 activity is not well understood today
as the expression levels of the corresponding cyclin subunit,
CycK, are rather stable. This is similar to other cyclins controlling
transcriptional CDKs, e.g., CycT1, but different from cell-cycle-
regulating cyclins such as CycA. The Cdk13 kinase is unusually
large with 690 residues preceding the kinase domain and 510
residues following the kinase domain. Regulation steps could
possibly be mediated by cellular localization or by intra-molecu-
lar interactions, e.g., via the N-terminal SR elements. Despite
being involved in constitutive and alternative splicing events,
SR proteins are thought to attach to newly made pre-mRNA to
prevent the pre-mRNA from binding to the coding DNA strand
to increase genome stabilization (Zhou and Fu, 2013).
The peptidyl-prolyl isomerase Pin1 does not change the phos-
phorylation preferences of the transcription elongation kinases
Cdk9, Cdk12, and Cdk13 (Figure 6). Using recombinant proteins
or flag-tag immuno-precipitated full-length proteins with the
corresponding cyclin subunits, we could not see any shift toward
increased Ser2 phosphorylation levels of the CTD. Likewise, the
activity of the kinases is not changed upon the presence of Pin1.
This result is similar to the recently published observation that
the Pin1 ortholog Ess1 from yeast does not stimulate the activity
of Cdk12 (Bartkowiak and Greenleaf, 2015). Whereas writing of
the CTD phosphorylations is not influenced by the isomerase,
dephosphorylation by the CTD phosphatase Fcp1 was shown to
be modulated by Pin1 (Xu et al., 2003). Hyper-phosphorylation of
the CTD thus correlates with the inhibition of Fcp1 by Pin1, whose
activity is high in early stages of the transcription cycle (Xu and
Manley, 2007). Yet, pre-incubation of the CTD with Cdk9/CycT1
resulting in a strong Ser5 phosphorylation signal led to a small
increase in pSer2 marks after exposure to either Cdk12 or Cdk13.
Despite the fact that Cdk13 and Cdk12 have similar kinase
domains and share the same regulating cyclin, both kinases
regulate expression of a largely different set of genes and biolog-Cical processes. Consistent with our expression analyses are re-
sults of a recent study showing that Cdk12 knockout leads to
an early post-implantation embryonal lethality in mice pointing
to a very specific and non-redundant role of Cdk13 and Cdk12
in development perhaps by the regulation of expression of
different gene sets (Chen et al., 2014b). Notably, the same study
showed that Cdk13 and Cdk12 regulate also expression of a
common gene, Cdk5, to direct axonal growth. The gene expres-
sion profiles are also consistent with a prominent role of Cdk12 in
the expression of the c-FOS proto-oncogene induced by the
epidermal growth factor (Eifler et al., 2015). Further evidence
pointing to different function of both kinases was provided by
knockdown of Cdk13 and Cdk12 in embryonic stem cells, which
resulted in differentiation via regulation of expression of different
sets of genes (Dai et al., 2012).
Cyclin-dependent kinases have evolved as important target
proteins for the treatment of multiple diseases, including cancer
and leukemia (Malumbres and Barbacid, 2009). Despite the Cdk/
cyclin pairs driving the cell cycle (interphase regulating Cdk2,
Cdk4, and Cdk6, and mitotic Cdk5), transcriptional CDKs 7, 8,
9, 12, and 13 are now increasingly recognized as important fac-
tors of tumor oncogenesis. Discovery of a covalent Cdk7 inhibi-
tor targeting a cysteine residue outside the canonical kinase
domain provided an unanticipatedmeans of achieving selectivity
(Kwiatkowski et al., 2014). Inhibition of Cdk9 activity has been
identified as another means to counteract cancer cell
progression, mixed lineage leukemia, and HIV (Wang and
Fischer, 2008). With the crystal structure of Cdk13/CycK deter-
mined, we provide the structural basis for targeted drug discov-
ery against this human kinase.
EXPERIMENTAL PROCEDURES
Plasmids and Proteins
Cdk13/CycK proteins were expressed in baculo-virus-infected Sf9 cells and
purified as described in the Supplemental Experimental Procedures.
Crystallization and Structure Determination
For crystallization, the purified Cdk13/CycK complex wasmixed at 85 mMcon-
centration with ADP, AlF3, MgCl2 and substrate peptide P-pS-YSPTSP-pS-
YSPT in molar ratios of 1:8:32:64:8 and incubated on ice for 30 min. Initial
crystals were obtained using the hanging drop vapor diffusion technique at
293 K. The crystal structure was determined and refined as described in the
Supplemental Experimental Procedures and Table S1.
RNA Polymerase II CTD Substrate Peptides
For kinase activity analyses, various CTD polypeptides were purchased from
Biosyntan or synthesized in house with 95% purity (high-performance liquid
chromatography [HPLC] grade). The peptide used for crystallization (ac-P-
pS-YSPTSP-pS-YSPT-amid) contained two phosphorylated serine residues
at heptad position 7. For quantitative analysis in electrospray ionization
mass spectrometry (ESI-MS) experiments or radioactive filter-binding assays,
CTD substrate peptides were marked at the C terminus with a double arginine
motif separated by a polyethylene glycol spacer. The arginines were set for
improved transfer rates in quantitative filter binding assays and for improved
ionization properties in ESI-MS analyses.
In Vitro Kinase Assays
Radioactive kinase reactions (typically 35 ml) were carried out with recombi-
nant, highly purified proteins using a standard protocol. In short, Cdk13/
CycK (0.2–0.5 mM) was pre-incubated with CTD substrates (peptides
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in kinase buffer (150 mM HEPES [pH 7.6], 34 mM KCl, 7 mM MgCl2, 2.5 mM
dithiothreitol, 5 mM b-glycerol phosphate, 1 3 PhosSTOP [Roche]). Cold
ATP (to a final concentration of 1–2 mM) and 3 mCi [32P]-g-ATP (Perkin-Elmer)
were added, and the reaction mixture was incubated up to 30 min at 30C at
350 rpm. Reactions were stopped by adding EDTA to a final concentration of
50mM. For reactions using GST-CTD, aliquots of 11 ml eachwere spotted onto
P81 Whatman paper squares. For substrate peptides, Optitran BA-S85 rein-
forced membrane was used. Paper squares were washed three times for
5 min with 0.75% (v/v) phosphoric acid, with at least 5 ml washing solution
per paper. Radioactivity was counted in a Beckman Scintillation Counter
(Beckman Coulter) for 1 min. Measurements were performed in triplicate
and are represented as mean with SD.
Kinase Assays with Flag-Tagged Proteins
Plasmids of full-length flag-tagged proteins, immuno-precipitations from cell
lysate, and kinase assays are described in the Supplemental Experimental
Procedures.
Short Interference RNA Transfections and Flavopiridol Treatment
HCT116 cells were plated at 20% confluency in 6-well plates in culture me-
dium without antibiotics. After 24 hr cultivation, transfections using Cdk12,
Cdk13 or control siRNA (Santa Cruz Biotechnology) were performed or cells
were just mock transfected. The transfections were done in a total volume of
2.5 ml containing 2.5 ml of 10 mM siRNA and 5 ml of Lipofectamine RNAiMax
(Invitrogene) according to the manufacturer’s instructions. Transfection mix
was removed 3 hr later, and cells were grown for another 69 hr in fresh media.
Mock-transfected cells were treated with flavopiridol (500 nM final concentra-
tion) 2 hr prior the cell harvest. Then, cells were lysed in buffer containing
20 mM HEPES/KOH (pH 7.9), 15% glycerol, 0.2% NP-40, 150 mM KCl,
1 mM DTT, 0.2 mM EDTA, and protease inhibitor (Sigma), and the CTD phos-
phorylations were analyzed by western blotting with phospho-specific
antibodies.
Western Blots
For western blot analysis, kinase assays were run with 0.2 mM Cdk13/CycK,
0.2 mM Cdk12/CycK, 5 mM Pin1, 5 mM Pin1DWW, 10 mM GST-CTD f.l., and
2 mM ATP in kinase buffer. After incubation with Cdk13/CycK, GST-CTD
proteins were subjected to SDS-PAGE on a 12% gel before transfer to nitro-
cellulose (GE Healthcare). Monoclonal antibodies specific for RNAPII CTD
phosphorylation sites pSer2 (3E10), pSer5 (3E8), and pSer7 (4E12) were
used as described previously (Bo¨sken et al., 2014). Membranes were stained
with chicken anti-rat immunoglobulin G (IgG) horseradish peroxidase (HRP)
secondary antibodies, and antibody recognition was revealed by enhanced
chemiluminescence.
Expression Microarrays
For expression microarrays HCT116 cells were transfected in triplicate with
1 ml of 10 mM CTRL, Cdk12, and Cdk13 siRNAs as described above. After
72 hr, cells were harvested and RNA isolated with miRNAeasy kit (QIAGEN)
according to the manufacturer’s instructions. A total of nine samples was
used: three from the siRNA CTRL, three from siRNA Cdk12, and three from
siRNA Cdk13 knockdowns. Human Gene 1.0ST microarrays from Affymetrix
were used. Details on sample preparation and data analyses are provided in
the Supplemental Information.
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